|
瑞士制药业巨擘罗氏大药厂（Roche Holding AG，ROG）于美国东部时间2月7日下午表示，临床试验显示其药物派罗欣（Pegasys）对丙型肝炎和爱滋病毒（HIV）感染者的疗效，较标准疗法要强。 罗氏称，一项针对近900人进行的临床试验发现，派罗欣与“Copegus”结合使用，对其中40%的病患产生了持续的病毒反应。“Copegus”是罗氏的标准抗病毒药物利巴韦林（ribavirin）的品牌名。 而接受传统干扰素加利巴韦林的治疗者中，只有12%的人产生了持续的病毒反应。 这项APRICOT试验的结果在旧金山的逆转录病毒和机会性感染大会（Conference on Retroviruses and Opportunistic Infections）上公布。 派罗欣是一种自然生成且持久存在的免疫系统蛋白质干扰素。该药于2002年12月在美国获核可。
Roche’s Pegasys Helps HIV, Hepatitis C Patients Sat February 7, 2004 03:00 PM ET ZURICH (Reuters) - A clinical trial has shown Roche Holding AG’s Pegasys drug works better than standard therapy in helping patients infected with both hepatitis C and the HIV virus that causes AIDS, Roche said on Saturday. A trial of nearly 900 people found Pegasys combined with Copegus, Roche’s brand of standard antiviral drug ribavirin, produced a sustained virological response in 40 percent of patients, the Swiss company said. This compares to 12 percent for co-infected patients who got conventional interferon plus ribavirin. Results of the so-called APRICOT trial were released at the Conference on Retroviruses and Opportunistic Infections in San Francisco. It was more good news for Roche from clinical trials about Pegasys, which has seen fast uptake as a treatment for hepatitis C and is being tested for other uses as well, including as a drug against hepatitis B. Pegasys is a long-lasting form of the naturally occurring protein interferon that stimulates the immune system and was approved in the United States in December 2002. Sales of Pegasys/Copegus soared to 942 million Swiss francs ($753 million) last year, making it Roche’s sixth-biggest drug. It has been wresting market share from Schering-Plough Corp’s rival Peg-Intron. This week Roche maintained for now its forecast that annual sales could peak at around two billion francs. ($1=1.251 Swiss Franc)
|